Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor.
about
Investigational drugs to treat methicillin-resistant Staphylococcus aureusRational Optimization of Drug-Target Residence Time: Insights from Inhibitor Binding to the Staphylococcus aureus FabI Enzyme–Product ComplexRational Design of Broad Spectrum Antibacterial Activity Based on a Clinically Relevant Enoyl-Acyl Carrier Protein (ACP) Reductase InhibitorResistance Mechanisms and the Future of Bacterial Enoyl-Acyl Carrier Protein Reductase (FabI) AntibioticsTranscriptional profiles of the response of methicillin-resistant Staphylococcus aureus to pentacyclic triterpenoidsChallenges of antibacterial discoveryRadiosynthesis and biological evaluation of a novel enoyl-ACP reductase inhibitor for Staphylococcus aureusThe MUT056399 inhibitor of FabI is a new antistaphylococcal compound.Mutations upstream of fabI in triclosan resistant Staphylococcus aureus strains are associated with elevated fabI gene expression.Escherichia coli ASKA Clone Library Harboring tRNA-Specific Adenosine Deaminase (tadA) Reveals Resistance towards Xanthorrhizol.The Francisella tularensis FabI enoyl-acyl carrier protein reductase gene is essential to bacterial viability and is expressed during infection.Environmental fatty acids enable emergence of infectious Staphylococcus aureus resistant to FASII-targeted antimicrobials.Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI).Inhibitors of fatty acid synthesis in prokaryotes and eukaryotes as anti-infective, anticancer and anti-obesity drugs.Recent advances in inhibitors of bacterial fatty acid synthesis type II (FASII) system enzymes as potential antibacterial agents.Antibiotic resistance in Staphylococcus aureus. Current status and future prospects.Recent Advances in the Rational Design and Optimization of Antibacterial Agents.Bacterial fatty acid metabolism in modern antibiotic discovery.What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.Benzimidazole-Based FabI Inhibitors: A Promising Novel Scaffold for Anti-staphylococcal Drug Development.Exogenous fatty acid metabolism in bacteria.Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics.Dissemination of Novel Antimicrobial Resistance Mechanisms through the Insertion Sequence Mediated Spread of Metabolic Genes.A pathway-directed positive growth restoration assay to facilitate the discovery of lipid A and fatty acid biosynthesis inhibitors in Acinetobacter baumannii.
P2860
Q26780246-93C2C90B-99F8-4E6B-9A65-C03800980293Q27678258-9FED2C4C-EE48-4567-90E9-5FD364702C01Q27683440-E4D5A599-5D0B-4356-B0F2-DC2895F0D27AQ28069943-955D3542-78D3-46D7-B94B-25E6A127B4B6Q28486248-66283770-456E-407B-831E-24A05DD8A3BCQ33793074-DF7F1ED6-C456-426D-8FC9-DC01CFD5ABB4Q34622399-A8AEF318-904C-4DFF-A944-01955DA59510Q35270339-413C9871-4B44-46C5-8C46-C8BB630EF2B0Q35618052-DF74A384-CCA1-4F87-90B2-B2857BAF41D3Q35775522-E2330C84-11F5-41E1-8AA6-D9973470334DQ36558861-2F7544F3-E9DB-4424-BB9C-81C900C781E2Q37329885-BB3588B8-B487-49D9-8519-8DC6AC6FDF11Q37404976-E01A2A11-48B7-48D0-9C29-E19B31F660B3Q38019608-BA62900A-F6FB-4517-B149-EB2312046DD3Q38124842-87DA5368-4B61-4F86-84ED-BFA2CAE9EF77Q38728885-5CF1CA6A-25D2-4093-B2DE-C854FE4F811CQ38958278-468A519A-91C1-4988-8B16-0D2E1FD69186Q38964523-0EFC2C80-9E95-4C7E-8FD8-145DF1A45ECCQ39120027-25DF86F2-8DE8-40C6-890A-75BB0321BA54Q39275601-D6B59F03-6C1F-4D95-8541-714C0F2584F8Q39408643-E53A8597-22F9-41DF-A34B-00D4F7998D86Q41855966-D494B4E0-C916-4791-8718-3F53CB463DF1Q42137262-AB0F92A2-C716-4F30-A59E-D4FCCE3F7579Q52689133-F58851AE-10DA-4017-8024-C9F382C186A1
P2860
Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Antistaphylococcal activities ...... in reductase (FabI) inhibitor.
@en
type
label
Antistaphylococcal activities ...... in reductase (FabI) inhibitor.
@en
prefLabel
Antistaphylococcal activities ...... in reductase (FabI) inhibitor.
@en
P2093
P356
P1476
Antistaphylococcal activities ...... in reductase (FabI) inhibitor.
@en
P2093
Cheol Min Kim
Hee Soo Park
Jeong Mi Kim
Jin-Hwan Kwak
Sung Ji Jung
Yu Min Yoon
P304
P356
10.1093/JAC/DKM236
P407
P577
2007-07-02T00:00:00Z